Clinical Trial

Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

Study acronym: ISIdE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
ISIdE is an European, multicentric study that aims to assess the efficacy of Sacituzumab Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherapy or within 6 months after the end of curative treatments in order to: 1. evaluate the treatment efficacy in less pretreated patients. 2. identify biomarkers that could predict response or resistance to the drug.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-09-20; most recent amendment 2026-07-20.
Status change: Recruiting → Active, Not Recruiting 2026-07-20
Status change: Not Yet Recruiting → Recruiting 2023-11-06
Trial Details
NCT Number NCT05552001
Lead Sponsor UNICANCER
Collaborators: Gilead Sciences
Conditions Triple Negative Breast Cancer, Metastatic Breast Cancer
Enrollment 96 participants
Start Date 2023-10-05
Primary Completion 2026-10-01 (estimated)
Study Completion 2028-05-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-21